Our Investor Proposition

Unlocking value for our shareholders

Our growing commercial business is funding Valneva’s exciting R&D pipeline

Stock Information

€2,46 +2,51% Last update: November 22, 2019 at 17:35 CET Stock Price

“We have the only clinical-stage vaccine program against Lyme disease worldwide.”

Valneva's CEO Thomas Lingelbach comments on Group Strategy

Valneva's 9M 2019 Interim Results (Conference-call)

Access Valneva's webcast, the analyst presentation, the press release and the financial statements below.

Upcoming Events

First nine months results 2019

Contact

Investor Relations Team

Campus Bio-Ouest
6, Rue Alain Bombard
44800 Saint-Herblain, France

T: +33 2 28 07 37 10 investors@valneva.com

Subscribe to Valneva News

Submit

Press Releases

November 18, 2019

Valneva Reports Excellent Final Phase 1 Results for its Chikungunya Vaccine Candidate, Confirms Plans

November 13, 2019

Valneva Announces Appointments of Two Leading Vaccine Experts to its Scientific Advisory Board

October 31, 2019

Valneva Raises Product Sales Guidance Following Strong Nine-Month Results and R&D Execution

View More